Ivarmacitinib for preserving insulin production in new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial is testing an oral medication called ivarmacitinib, which may help protect the insulin-making cells in your pancreas and slow down the progression of type 1 diabetes. It is designed for people who have just been diagnosed with type 1 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of type 1 diabetes.
- You must be able to start treatment within 100 days of your formal diagnosis.
- Your body must still be making some insulin, which will be checked with a special test.
- You must have tested positive for at least one diabetes-related antibody.
- You cannot have other active autoimmune diseases (except stable thyroid disease) or serious infections like HIV, hepatitis, or tuberculosis.
- You cannot have severe liver or kidney problems, or have recently had major heart issues or surgery.
- You cannot have taken certain immune-system medications before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ivarmacitinib to see if it can help your body's immune system fight triple-negative breast cancer when immunotherapy alone has stopped working. It is a pill you take by mouth, and this study is in phase 2, meaning it's being tested for effectiveness in a larger group.
This trial tests if baricitinib, a pill that calms the immune system, can protect the remaining insulin-making cells in people newly diagnosed with type 1 diabetes. If it works, you might keep making some of your own insulin longer.
This study tests a pill called Ivarmacitinib (a JAK inhibitor) for people with advanced solid tumors who had to stop immunotherapy because of side effects. The drug aims to calm the immune system and may help you restart cancer treatment.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This trial tests if baricitinib, a pill that calms the immune system, can slow down or delay the onset of type 1 diabetes in children and adults who are at high risk. It is for people whose blood sugar is already starting to rise but who do not yet need insulin.
This trial tests whether the drug sorafenib can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may slow the progression of the disease and reduce the need for insulin injections.
Hear when a new T1DM - Type 1 Diabetes Mellitus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.